Oruka Therapeutics Secures $700M Public Offering, New Halozyme Partnership, and Extends Cash Runway

summarizeSummary

Oruka Therapeutics reported a successful $700.4 million public offering and a new collaboration with Halozyme, significantly boosting its cash reserves and extending its operational runway. The company also reiterated positive clinical trial data for its lead drug candidate, ORKA-001.

check_boxKey Events

• Successful Public Offering

  The company closed an upsized public offering on April 30, 2026, raising $700.4 million in gross proceeds by selling 9.66 million shares at $72.50 per share. This significantly enhances liquidity and was priced at a premium to the current stock price.

• New Strategic Collaboration

  On May 1, 2026, Oruka Therapeutics entered into a global exclusive collaboration and license agreement with Halozyme Hypercon, Inc., involving an upfront payment and potential milestone payments of up to $176.5 million, plus mid-single digit royalties.

• Extended Cash Runway

  With the proceeds from the recent offering, the company expects its existing cash, cash equivalents, and marketable securities of $496.0 million (as of March 31, 2026) to fund operating plans for at least twelve months from the filing date.

• Positive Clinical Trial Update

  The report highlights strong Week 16 data from the Phase 2a EVERLAST-A trial for ORKA-001 in psoriasis, with 63.5% of participants achieving PASI 100, consistent with prior disclosures.

auto_awesomeAnalysis

This quarterly report highlights significant positive developments that materially strengthen Oruka Therapeutics' financial position and pipeline. The successful $700.4 million public offering, completed just after the quarter end, provides substantial capital, extending the company's cash runway for over 12 months. This financing, coupled with a new collaboration agreement with Halozyme worth up to $176.5 million in milestones, validates the company's technology and future prospects. The report also reiterates positive Phase 2a clinical trial data for its lead program, ORKA-001, which is crucial for a clinical-stage biotech. While net losses increased, this is expected as the company advances its costly R&D programs, and the recent capital raises significantly de-risk its operations.